Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
8 evidence topics · 10 sources
Ersodetug: tumor types enrolled and participants not yet responding in upLIFT, preliminary
Ersodetug: response by tumor type (insulinoma or NICTH) in upLIFT
No evidence found.
Ersodetug: non-responder with advanced cancer and poor performance status, upLIFT interim
Ersodetug: dose escalation and partial response in the expanded access series
“One participant required escalation from 9 to 12 mg/kg every other week.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One individual on home TPN initiated ersodetug contemporaneously with ablation of primary hepatic metastases, ultimately achieving a 50% reduction in intravenous carbohydrate support after dose escalation of ersodetug to 9 mg/kg biweekly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparator therapies: effectiveness differs between insulin-mediated and IGF-2-mediated hypoglycemia
Comparator therapies: somatostatin receptor expression in indolent and aggressive insulinoma
“Expression of the SSTR2 and SSTR5 is generally low in indolent insulinoma cells, but usually high in aggressive insulinomas” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This test is required to avoid and timely intervene for a paradoxical aggravation of hypoglycemia via the suppression of counterregulatory glucagon secretion in patients with insulinomas which lack SSTR2 expression” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PRRT: tumor grade and recurrence of hypoglycemia
Hepatic artery embolization: timing of hypoglycemia recurrence and survival
“Recurrence of hypoglycemia within 6 weeks of the first HAE was associated with a median OS of 8.5 months, and recurrence greater than 6 weeks post-HAE was associated with a median OS of 32.6 months (P = .03)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NICTH: tumor origin and chronic liver disease as outcome modifiers
“Chronic liver disease (CLD) was more likely to be associated with death than recovery (OR: 7.23, P: 0.03).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fibrous tumours were significantly associated with recovery compared to non‐fibrous ones, and the association was statistically significant (65.1% vs. 33%, p < .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote